FUJIFILM Diosynth Biotechnologies vs Piramal Pharma Solutions: CDMO Comparison
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Piramal Pharma Solutions has more FDA inspections on record (5 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- FUJIFILM Diosynth Biotechnologies has materially broader EMA GMP coverage (12 active certificates vs 1) — stronger EU footprint.
On a 13-modality CDMO landscape, both FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions qualify as Biologics manufacturers; Piramal Pharma Solutions carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs Piramal Pharma Solutions
Which has the stronger FDA inspection record, FUJIFILM Diosynth Biotechnologies or Piramal Pharma Solutions?
Both FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record; Piramal Pharma Solutions has 5.
How do FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 12 active EMA GMP certificates and 6 MHRA / UK certificates. Piramal Pharma Solutions holds 1 active EMA GMP certificate and 12 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Biologics manufacturing — FUJIFILM Diosynth Biotechnologies or Piramal Pharma Solutions?
Both FUJIFILM Diosynth Biotechnologies and Piramal Pharma Solutions are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 84/100 and Piramal Pharma Solutions carries 84/100 — essentially tied for Piramal Pharma Solutions. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →